HT 2157

Drug Profile

HT 2157

Alternative Names: HT-2157

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator Lundbeck A/S
  • Developer Dart NeuroScience
  • Class Nootropics
  • Mechanism of Action Galanin type 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Major depressive disorder; Memory disorders

Most Recent Events

  • 16 Feb 2016 Discontinued - Preclinical for Memory disorders in USA (PO)
  • 16 Feb 2016 Discontinued - Phase-II for Major depressive disorder in USA (PO) (NeuroScience pipeline, August 2015)
  • 12 Apr 2013 Phase-II clinical trials in Major depressive disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top